APO Research
Talk to an analyst

APO RESEARCH · REPORT

Peripheral Vasodilator Drugs

Compare research editions
View pricing & licenses

Selected research

Industry Research

Peripheral Vasodilator Drugs Industry Research Report 2026

23 December 2025134 pages

Choose your research edition.

Industry ResearchPeripheral Vasodilator Drugs Industry Research Report 2026134 pages · $2,950 USDIndustry Growth & TrendsGlobal Peripheral Vasodilator Drugs Industry Growth and Trends Forecast to 2032117 pages · $3,450 USDMarket StructureGlobal Peripheral Vasodilator Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032192 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Peripheral Vasodilator Drugs Market Outlook and Growth Opportunities 2026200 pages · $4,250 USDMarket Analysis & ForecastGlobal Peripheral Vasodilator Drugs Market Analysis and Forecast 2026-2032206 pages · $4,950 USD

Market perspective

The global Peripheral Vasodilator Drugs market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.

The North America market for Peripheral Vasodilator Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.

The Europe market for Peripheral Vasodilator Drugs is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.

Read the full market overview

The Asia Pacific market for Peripheral Vasodilator Drugs is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.

Leading global manufacturers of Peripheral Vasodilator Drugs include Endovastec, Aotecar Medical-B, Tibet Cheezheng Tibetan Medicine Co., Ltd, Teva Pharmaceutical Industries Ltd., Sanofi, Novartis AG, Pfizer, Inc., GSK plc and Bayer AG, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report quantifies the global Peripheral Vasodilator Drugs market in terms of revenue (US$ million) and, where applicable, sales volume (k units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.

It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10).

The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.

Key Companies & Market Share Insights

This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.

Peripheral Vasodilator Drugs Market by Company

Endovastec

Aotecar Medical-B

Tibet Cheezheng Tibetan Medicine Co., Ltd

Teva Pharmaceutical Industries Ltd.

Sanofi

Novartis AG

Pfizer, Inc.

GSK plc

Bayer AG

Bat Medical

AstraZeneca

Viatris, Inc.

Sun Pharmaceutical Industries Ltd.

Merck & Co., Inc.

Lupin

Bristol-Myers Squibb Company

Boehringer Ingelheim International GmbH

Abbott Laboratories

Peripheral Vasodilator Drugs Segment by Type

Alpha-adrenergic Blockers

Calcium Channel Blockers

Potassium Channel Activators

Others

Peripheral Vasodilator Drugs Segment by Application

Hospital

Retail Pharmacies

Others

Peripheral Vasodilator Drugs Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Peripheral Vasodilator Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Peripheral Vasodilator Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market

5. This report helps stakeholders to gain insights into which regions to target globally

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Peripheral Vasodilator Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Research objectives, research methods, data sources, data cross-validation;

Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 3: Detailed analysis of Peripheral Vasodilator Drugs manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.

Chapter 5: Production/output, value of Peripheral Vasodilator Drugs by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.

Chapter 6: Consumption of Peripheral Vasodilator Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.

Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 11: The main points and conclusions of the report.

More report detail

Tables and figures
List of Tables Table 1. Secondary Sources Table 2. Primary Sources Table 3. Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 4. Market Value Comparison by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 5. Global Peripheral Vasodilator Drugs Volume and Revenue Market Size and CAGR of Manufacturers (2021 Versus 2025) Table 6. Global Peripheral Vasodilator Drugs Sales (k units) of Manufacturers (2021-2026) Table 7. Global Peripheral Vasodilator Drugs Sales Market Share by Manufacturers (2021-2026) Table 8. Global Peripheral Vasodilator Drugs Revenue of Manufacturers (2021-2026) Table 9. Global Peripheral Vasodilator Drugs Revenue Share by Manufacturers (2021-2026) Table 10. Global Market Peripheral Vasodilator Drugs Average Price (USD/unit) of Manufacturers (2021-2026) Table 11. Global Peripheral Vasodilator Drugs Industry Ranking, 2024 VS 2025 VS 2026 Table 12. Global Manufacturers of Peripheral Vasodilator Drugs, Manufacturing Sites & Headquarters Table 13. Global Manufacturers of Peripheral Vasodilator Drugs, Product Type & Application Table 14. Global Peripheral Vasodilator Drugs Manufacturers Established Date Table 15. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 16. Global Peripheral Vasodilator Drugs by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 17. Manufacturers Mergers & Acquisitions, Expansion Plans) Table 18. Endovastec Company Information Table 19. Endovastec Business Overview Table 20. Endovastec Peripheral Vasodilator Drugs Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 21. Endovastec Peripheral Vasodilator Drugs Product Portfolio Table 22. Endovastec Recent Developments Table 23. Aotecar Medical-B Company Information Table 24. Aotecar Medical-B Business Overview Table 25. Aotecar Medical-B Peripheral Vasodilator Drugs Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 26. Aotecar Medical-B Peripheral Vasodilator Drugs Product Portfolio Table 27. Aotecar Medical-B Recent Developments Table 28. Tibet Cheezheng Tibetan Medicine Co., Ltd Company Information Table 29. Tibet Cheezheng Tibetan Medicine Co., Ltd Business Overview Table 30. Tibet Cheezheng Tibetan Medicine Co., Ltd Peripheral Vasodilator Drugs Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 31. Tibet Cheezheng Tibetan Medicine Co., Ltd Peripheral Vasodilator Drugs Product Portfolio Table 32. Tibet Cheezheng Tibetan Medicine Co., Ltd Recent Developments Table 33. Teva Pharmaceutical Industries Ltd. Company Information Table 34. Teva Pharmaceutical Industries Ltd. Business Overview Table 35. Teva Pharmaceutical Industries Ltd. Peripheral Vasodilator Drugs Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 36. Teva Pharmaceutical Industries Ltd. Peripheral Vasodilator Drugs Product Portfolio Table 37. Teva Pharmaceutical Industries Ltd. Recent Developments Table 38. Sanofi Company Information Table 39. Sanofi Business Overview Table 40. Sanofi Peripheral Vasodilator Drugs Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 41. Sanofi Peripheral Vasodilator Drugs Product Portfolio Table 42. Sanofi Recent Developments Table 43. Novartis AG Company Information Table 44. Novartis AG Business Overview Table 45. Novartis AG Peripheral Vasodilator Drugs Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 46. Novartis AG Peripheral Vasodilator Drugs Product Portfolio Table 47. Novartis AG Recent Developments Table 48. Pfizer, Inc. Company Information Table 49. Pfizer, Inc. Business Overview Table 50. Pfizer, Inc. Peripheral Vasodilator Drugs Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 51. Pfizer, Inc. Peripheral Vasodilator Drugs Product Portfolio Table 52. Pfizer, Inc. Recent Developments Table 53. GSK plc Company Information Table 54. GSK plc Business Overview Table 55. GSK plc Peripheral Vasodilator Drugs Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 56. GSK plc Peripheral Vasodilator Drugs Product Portfolio Table 57. GSK plc Recent Developments Table 58. Bayer AG Company Information Table 59. Bayer AG Business Overview Table 60. Bayer AG Peripheral Vasodilator Drugs Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 61. Bayer AG Peripheral Vasodilator Drugs Product Portfolio Table 62. Bayer AG Recent Developments Table 63. Bat Medical Company Information Table 64. Bat Medical Business Overview Table 65. Bat Medical Peripheral Vasodilator Drugs Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 66. Bat Medical Peripheral Vasodilator Drugs Product Portfolio Table 67. Bat Medical Recent Developments Table 68. AstraZeneca Company Information Table 69. AstraZeneca Business Overview Table 70. AstraZeneca Peripheral Vasodilator Drugs Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 71. AstraZeneca Peripheral Vasodilator Drugs Product Portfolio Table 72. AstraZeneca Recent Developments Table 73. Viatris, Inc. Company Information Table 74. Viatris, Inc. Business Overview Table 75. Viatris, Inc. Peripheral Vasodilator Drugs Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 76. Viatris, Inc. Peripheral Vasodilator Drugs Product Portfolio Table 77. Viatris, Inc. Recent Developments Table 78. Sun Pharmaceutical Industries Ltd. Company Information Table 79. Sun Pharmaceutical Industries Ltd. Business Overview Table 80. Sun Pharmaceutical Industries Ltd. Peripheral Vasodilator Drugs Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 81. Sun Pharmaceutical Industries Ltd. Peripheral Vasodilator Drugs Product Portfolio Table 82. Sun Pharmaceutical Industries Ltd. Recent Developments Table 83. Merck & Co., Inc. Company Information Table 84. Merck & Co., Inc. Business Overview Table 85. Merck & Co., Inc. Peripheral Vasodilator Drugs Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 86. Merck & Co., Inc. Peripheral Vasodilator Drugs Product Portfolio Table 87. Merck & Co., Inc. Recent Developments Table 88. Lupin Company Information Table 89. Lupin Business Overview Table 90. Lupin Peripheral Vasodilator Drugs Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 91. Lupin Peripheral Vasodilator Drugs Product Portfolio Table 92. Lupin Recent Developments Table 93. Bristol-Myers Squibb Company Company Information Table 94. Bristol-Myers Squibb Company Business Overview Table 95. Bristol-Myers Squibb Company Peripheral Vasodilator Drugs Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 96. Bristol-Myers Squibb Company Peripheral Vasodilator Drugs Product Portfolio Table 97. Bristol-Myers Squibb Company Recent Developments Table 98. Boehringer Ingelheim International GmbH Company Information Table 99. Boehringer Ingelheim International GmbH Business Overview Table 100. Boehringer Ingelheim International GmbH Peripheral Vasodilator Drugs Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 101. Boehringer Ingelheim International GmbH Peripheral Vasodilator Drugs Product Portfolio Table 102. Boehringer Ingelheim International GmbH Recent Developments Table 103. Abbott Laboratories Company Information Table 104. Abbott Laboratories Business Overview Table 105. Abbott Laboratories Peripheral Vasodilator Drugs Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 106. Abbott Laboratories Peripheral Vasodilator Drugs Product Portfolio Table 107. Abbott Laboratories Recent Developments Table 108. Global Peripheral Vasodilator Drugs Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Table 109. Global Peripheral Vasodilator Drugs Sales by Region (2021-2026) & (k units) Table 110. Global Peripheral Vasodilator Drugs Sales Market Share by Region (2021-2026) Table 111. Global Peripheral Vasodilator Drugs Sales by Region (2027-2032) & (k units) Table 112. Global Peripheral Vasodilator Drugs Sales Market Share by Region (2027-2032) Table 113. Global Peripheral Vasodilator Drugs Revenue by Region (2021-2026) & (US$ Million) Table 114. Global Peripheral Vasodilator Drugs Revenue Market Share by Region (2021-2026) Table 115. Global Peripheral Vasodilator Drugs Revenue by Region (2027-2032) & (US$ Million) Table 116. Global Peripheral Vasodilator Drugs Revenue Market Share by Region (2027-2032) Table 117. North America Peripheral Vasodilator Drugs Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 118. North America Peripheral Vasodilator Drugs Sales by Country (2021-2026) & (k units) Table 119. North America Peripheral Vasodilator Drugs Sales by Country (2027-2032) & (k units) Table 120. North America Peripheral Vasodilator Drugs Revenue by Country (2021-2026) & (US$ Million) Table 121. North America Peripheral Vasodilator Drugs Revenue by Country (2027-2032) & (US$ Million) Table 122. Europe Peripheral Vasodilator Drugs Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 123. Europe Peripheral Vasodilator Drugs Sales by Country (2021-2026) & (k units) Table 124. Europe Peripheral Vasodilator Drugs Sales by Country (2027-2032) & (k units) Table 125. Europe Peripheral Vasodilator Drugs Revenue by Country (2021-2026) & (US$ Million) Table 126. Europe Peripheral Vasodilator Drugs Revenue by Country (2027-2032) & (US$ Million) Table 127. Asia Pacific Peripheral Vasodilator Drugs Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 128. Asia Pacific Peripheral Vasodilator Drugs Sales by Country (2021-2026) & (k units) Table 129. Asia Pacific Peripheral Vasodilator Drugs Sales by Country (2027-2032) & (k units) Table 130. Asia Pacific Peripheral Vasodilator Drugs Revenue by Country (2021-2026) & (US$ Million) Table 131. Asia Pacific Peripheral Vasodilator Drugs Revenue by Country (2027-2032) & (US$ Million) Table 132. South America Peripheral Vasodilator Drugs Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 133. South America Peripheral Vasodilator Drugs Sales by Country (2021-2026) & (k units) Table 134. South America Peripheral Vasodilator Drugs Sales by Country (2027-2032) & (k units) Table 135. South America Peripheral Vasodilator Drugs Revenue by Country (2021-2026) & (US$ Million) Table 136. South America Peripheral Vasodilator Drugs Revenue by Country (2027-2032) & (US$ Million) Table 137. Middle East and Africa Peripheral Vasodilator Drugs Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 138. Middle East and Africa Peripheral Vasodilator Drugs Sales by Country (2021-2026) & (k units) Table 139. Middle East and Africa Peripheral Vasodilator Drugs Sales by Country (2027-2032) & (k units) Table 140. Middle East and Africa Peripheral Vasodilator Drugs Revenue by Country (2021-2026) & (US$ Million) Table 141. Middle East and Africa Peripheral Vasodilator Drugs Revenue by Country (2027-2032) & (US$ Million) Table 142. Global Peripheral Vasodilator Drugs Sales by Type (2021-2026) & (k units) Table 143. Global Peripheral Vasodilator Drugs Sales by Type (2027-2032) & (k units) Table 144. Global Peripheral Vasodilator Drugs Sales Market Share by Type (2021-2026) Table 145. Global Peripheral Vasodilator Drugs Sales Market Share by Type (2027-2032) Table 146. Global Peripheral Vasodilator Drugs Revenue by Type (2021-2026) & (US$ Million) Table 147. Global Peripheral Vasodilator Drugs Revenue by Type (2027-2032) & (US$ Million) Table 148. Global Peripheral Vasodilator Drugs Revenue Market Share by Type (2021-2026) Table 149. Global Peripheral Vasodilator Drugs Revenue Market Share by Type (2027-2032) Table 150. Global Peripheral Vasodilator Drugs Price by Type (2021-2026) & (USD/unit) Table 151. Global Peripheral Vasodilator Drugs Price by Type (2027-2032) & (USD/unit) Table 152. Global Peripheral Vasodilator Drugs Sales by Application (2021-2026) & (k units) Table 153. Global Peripheral Vasodilator Drugs Sales by Application (2027-2032) & (k units) Table 154. Global Peripheral Vasodilator Drugs Sales Market Share by Application (2021-2026) Table 155. Global Peripheral Vasodilator Drugs Sales Market Share by Application (2027-2032) Table 156. Global Peripheral Vasodilator Drugs Revenue by Application (2021-2026) & (US$ Million) Table 157. Global Peripheral Vasodilator Drugs Revenue by Application (2027-2032) & (US$ Million) Table 158. Global Peripheral Vasodilator Drugs Revenue Market Share by Application (2021-2026) Table 159. Global Peripheral Vasodilator Drugs Revenue Market Share by Application (2027-2032) Table 160. Global Peripheral Vasodilator Drugs Price by Application (2021-2026) & (USD/unit) Table 161. Global Peripheral Vasodilator Drugs Price by Application (2027-2032) & (USD/unit) Table 162. Key Raw Materials Table 163. Raw Materials Key Suppliers Table 164. Peripheral Vasodilator Drugs Distributors List Table 165. Peripheral Vasodilator Drugs Customers List Table 166. Peripheral Vasodilator Drugs Industry Trends Table 167. Peripheral Vasodilator Drugs Industry Drivers Table 168. Peripheral Vasodilator Drugs Industry Restraints Table 169. Authors List of This Report List of Figures Figure 1. Research Methodology Figure 2. Research Process Figure 3. Key Executives Interviewed Figure 4. Peripheral Vasodilator Drugs Product Image Figure 5. Global Peripheral Vasodilator Drugs Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 6. Global Peripheral Vasodilator Drugs Market Size (2021-2032) & (US$ Million) Figure 7. Global Peripheral Vasodilator Drugs Sales (2021-2032) & (k units) Figure 8. Global Peripheral Vasodilator Drugs Average Price (USD/unit) & (2021-2032) Figure 9. Alpha-adrenergic Blockers Product Image Figure 10. Calcium Channel Blockers Product Image Figure 11. Potassium Channel Activators Product Image Figure 12. Others Product Image Figure 13. Hospital Product Image Figure 14. Retail Pharmacies Product Image Figure 15. Others Product Image Figure 16. Global Peripheral Vasodilator Drugs Revenue Share by Manufacturers in 2025 Figure 17. Global Manufacturers of Peripheral Vasodilator Drugs, Manufacturing Sites & Headquarters Figure 18. Global Top 5 and 10 Peripheral Vasodilator Drugs Players Market Share by Revenue in 2025 Figure 19. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 20. Global Peripheral Vasodilator Drugs Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Figure 21. Global Peripheral Vasodilator Drugs Sales by Region in 2025 Figure 22. Global Peripheral Vasodilator Drugs Revenue by Region in 2025 Figure 23. North America Peripheral Vasodilator Drugs Market Size by Country in 2025 Figure 24. North America Peripheral Vasodilator Drugs Sales Market Share by Country (2021-2032) Figure 25. North America Peripheral Vasodilator Drugs Revenue Market Share by Country (2021-2032) Figure 26. United States Peripheral Vasodilator Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 27. Canada Peripheral Vasodilator Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 28. Mexico Peripheral Vasodilator Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 29. Europe Peripheral Vasodilator Drugs Market Size by Country in 2025 Figure 30. Europe Peripheral Vasodilator Drugs Sales Market Share by Country (2021-2032) Figure 31. Europe Peripheral Vasodilator Drugs Revenue Market Share by Country (2021-2032) Figure 32. Germany Peripheral Vasodilator Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 33. France Peripheral Vasodilator Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 34. U.K. Peripheral Vasodilator Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 35. Italy Peripheral Vasodilator Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 36. Russia Peripheral Vasodilator Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 37. Spain Peripheral Vasodilator Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 38. Netherlands Peripheral Vasodilator Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 39. Switzerland Peripheral Vasodilator Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 40. Sweden Peripheral Vasodilator Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 41. Poland Peripheral Vasodilator Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 42. Asia Pacific Peripheral Vasodilator Drugs Market Size by Country in 2025 Figure 43. Asia Pacific Peripheral Vasodilator Drugs Sales Market Share by Country (2021-2032) Figure 44. Asia Pacific Peripheral Vasodilator Drugs Revenue Market Share by Country (2021-2032) Figure 45. China Peripheral Vasodilator Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 46. Japan Peripheral Vasodilator Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 47. South Korea Peripheral Vasodilator Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 48. India Peripheral Vasodilator Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 49. Australia Peripheral Vasodilator Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 50. Taiwan Peripheral Vasodilator Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 51. Southeast Asia Peripheral Vasodilator Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 52. Southeast Asia Peripheral Vasodilator Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 53. South America Peripheral Vasodilator Drugs Market Size by Country in 2025 Figure 54. South America Peripheral Vasodilator Drugs Sales Market Share by Country (2021-2032) Figure 55. South America Peripheral Vasodilator Drugs Revenue Market Share by Country (2021-2032) Figure 56. Brazil Peripheral Vasodilator Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 57. Argentina Peripheral Vasodilator Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 58. Chile Peripheral Vasodilator Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 59. Middle East and Africa Peripheral Vasodilator Drugs Market Size by Country in 2025 Figure 60. Middle East and Africa Peripheral Vasodilator Drugs Sales Market Share by Country (2021-2032) Figure 61. Middle East and Africa Peripheral Vasodilator Drugs Revenue Market Share by Country (2021-2032) Figure 62. Egypt Peripheral Vasodilator Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 63. South Africa Peripheral Vasodilator Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 64. Israel Peripheral Vasodilator Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 65. Türkiye Peripheral Vasodilator Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 66. GCC Countries Peripheral Vasodilator Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 67. Global Peripheral Vasodilator Drugs Sales Market Share by Type (2021-2032) Figure 68. Global Peripheral Vasodilator Drugs Revenue Market Share by Type (2021-2032) Figure 69. Global Peripheral Vasodilator Drugs Price (USD/unit) by Type (2021-2032) Figure 70. Global Peripheral Vasodilator Drugs Sales Market Share by Application (2021-2032) Figure 71. Global Peripheral Vasodilator Drugs Revenue Market Share by Application (2021-2032) Figure 72. Global Peripheral Vasodilator Drugs Price (USD/unit) by Application (2021-2032) Figure 73. Peripheral Vasodilator Drugs Value Chain Figure 74. Peripheral Vasodilator Drugs Production Mode & Process Figure 75. Direct Comparison with Distribution Share Figure 76. Distributors Profiles Figure 77. Peripheral Vasodilator Drugs Industry Opportunities and Challenges

Scope & coverage.

Types
  • Alpha-adrenergic Blockers
  • Calcium Channel Blockers
  • Potassium Channel Activators
  • Others
Applications
  • Hospital
  • Retail Pharmacies
  • Others
Companies covered
  • Endovastec
  • Aotecar Medical-B
  • Tibet Cheezheng Tibetan Medicine Co., Ltd
  • Teva Pharmaceutical Industries Ltd.
  • Sanofi
  • Novartis AG
  • Pfizer, Inc.
  • GSK plc
  • Bayer AG
  • Bat Medical
  • AstraZeneca
  • Viatris, Inc.
  • Sun Pharmaceutical Industries Ltd.
  • Merck & Co., Inc.
  • Lupin
  • Bristol-Myers Squibb Company
  • Boehringer Ingelheim International GmbH
  • Abbott Laboratories

Inside the report.

1 Preface
  1. 1.1 Scope of Report
  2. 1.2 Reasons for Doing This Study
  3. 1.3 Research Methodology
  4. 1.4 Research Process
  5. 1.5 Data Source
  6. 1.5.1 Secondary Sources
  7. 1.5.2 Primary Sources
2 Market Overview
  1. 2.1 Product Definition
  2. 2.2 Global Market Growth Prospects
  3. 2.2.1 Global Peripheral Vasodilator Drugs Market Size (2021-2032)
  4. 2.2.2 Global Peripheral Vasodilator Drugs Sales (2021-2032)
  5. 2.2.3 Global Peripheral Vasodilator Drugs Market Average Price (2021-2032)
  6. 2.3 Peripheral Vasodilator Drugs by Type
  7. 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
  8. 2.3.2 Alpha-adrenergic Blockers
  9. 2.3.3 Calcium Channel Blockers
  10. 2.3.4 Potassium Channel Activators
  11. 2.3.5 Others
  12. 2.4 Peripheral Vasodilator Drugs by Application
  13. 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
  14. 2.4.2 Hospital
  15. 2.4.3 Retail Pharmacies
  16. 2.4.4 Others
3 Market Competitive Landscape by Manufacturers
  1. 3.1 Global Peripheral Vasodilator Drugs Market Competitive Situation by Manufacturers (2021 Versus 2025)
  2. 3.2 Global Peripheral Vasodilator Drugs Sales (k units) of Manufacturers (2021-2026)
  3. 3.3 Global Peripheral Vasodilator Drugs Revenue of Manufacturers (2021-2026)
  4. 3.4 Global Peripheral Vasodilator Drugs Average Price by Manufacturers (2021-2026)
  5. 3.5 Global Peripheral Vasodilator Drugs Industry Ranking, 2024 VS 2025 VS 2026
  6. 3.6 Global Manufacturers of Peripheral Vasodilator Drugs, Manufacturing Sites & Headquarters
  7. 3.7 Global Manufacturers of Peripheral Vasodilator Drugs, Product Type & Application
  8. 3.8 Global Manufacturers of Peripheral Vasodilator Drugs, Established Date
  9. 3.9 Global Peripheral Vasodilator Drugs Market CR5 and HHI
  10. 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
  1. 4.1 Endovastec
  2. 4.1.1 Endovastec Company Information
  3. 4.1.2 Endovastec Business Overview
  4. 4.1.3 Endovastec Peripheral Vasodilator Drugs Sales, Revenue and Gross Margin (2021-2026)
  5. 4.1.4 Endovastec Peripheral Vasodilator Drugs Product Portfolio
  6. 4.1.5 Endovastec Recent Developments
  7. 4.2 Aotecar Medical-B
  8. 4.2.1 Aotecar Medical-B Company Information
  9. 4.2.2 Aotecar Medical-B Business Overview
  10. 4.2.3 Aotecar Medical-B Peripheral Vasodilator Drugs Sales, Revenue and Gross Margin (2021-2026)
  11. 4.2.4 Aotecar Medical-B Peripheral Vasodilator Drugs Product Portfolio
  12. 4.2.5 Aotecar Medical-B Recent Developments
  13. 4.3 Tibet Cheezheng Tibetan Medicine Co., Ltd
  14. 4.3.1 Tibet Cheezheng Tibetan Medicine Co., Ltd Company Information
  15. 4.3.2 Tibet Cheezheng Tibetan Medicine Co., Ltd Business Overview
  16. 4.3.3 Tibet Cheezheng Tibetan Medicine Co., Ltd Peripheral Vasodilator Drugs Sales, Revenue and Gross Margin (2021-2026)
  17. 4.3.4 Tibet Cheezheng Tibetan Medicine Co., Ltd Peripheral Vasodilator Drugs Product Portfolio
  18. 4.3.5 Tibet Cheezheng Tibetan Medicine Co., Ltd Recent Developments
  19. 4.4 Teva Pharmaceutical Industries Ltd.
  20. 4.4.1 Teva Pharmaceutical Industries Ltd. Company Information
  21. 4.4.2 Teva Pharmaceutical Industries Ltd. Business Overview
  22. 4.4.3 Teva Pharmaceutical Industries Ltd. Peripheral Vasodilator Drugs Sales, Revenue and Gross Margin (2021-2026)
  23. 4.4.4 Teva Pharmaceutical Industries Ltd. Peripheral Vasodilator Drugs Product Portfolio
  24. 4.4.5 Teva Pharmaceutical Industries Ltd. Recent Developments
  25. 4.5 Sanofi
  26. 4.5.1 Sanofi Company Information
  27. 4.5.2 Sanofi Business Overview
  28. 4.5.3 Sanofi Peripheral Vasodilator Drugs Sales, Revenue and Gross Margin (2021-2026)
  29. 4.5.4 Sanofi Peripheral Vasodilator Drugs Product Portfolio
  30. 4.5.5 Sanofi Recent Developments
  31. 4.6 Novartis AG
  32. 4.6.1 Novartis AG Company Information
  33. 4.6.2 Novartis AG Business Overview
  34. 4.6.3 Novartis AG Peripheral Vasodilator Drugs Sales, Revenue and Gross Margin (2021-2026)
  35. 4.6.4 Novartis AG Peripheral Vasodilator Drugs Product Portfolio
  36. 4.6.5 Novartis AG Recent Developments
  37. 4.7 Pfizer, Inc.
  38. 4.7.1 Pfizer, Inc. Company Information
  39. 4.7.2 Pfizer, Inc. Business Overview
  40. 4.7.3 Pfizer, Inc. Peripheral Vasodilator Drugs Sales, Revenue and Gross Margin (2021-2026)
  41. 4.7.4 Pfizer, Inc. Peripheral Vasodilator Drugs Product Portfolio
  42. 4.7.5 Pfizer, Inc. Recent Developments
  43. 4.8 GSK plc
  44. 4.8.1 GSK plc Company Information
  45. 4.8.2 GSK plc Business Overview
  46. 4.8.3 GSK plc Peripheral Vasodilator Drugs Sales, Revenue and Gross Margin (2021-2026)
  47. 4.8.4 GSK plc Peripheral Vasodilator Drugs Product Portfolio
  48. 4.8.5 GSK plc Recent Developments
  49. 4.9 Bayer AG
  50. 4.9.1 Bayer AG Company Information
  51. 4.9.2 Bayer AG Business Overview
  52. 4.9.3 Bayer AG Peripheral Vasodilator Drugs Sales, Revenue and Gross Margin (2021-2026)
  53. 4.9.4 Bayer AG Peripheral Vasodilator Drugs Product Portfolio
  54. 4.9.5 Bayer AG Recent Developments
  55. 4.10 Bat Medical
  56. 4.10.1 Bat Medical Company Information
  57. 4.10.2 Bat Medical Business Overview
  58. 4.10.3 Bat Medical Peripheral Vasodilator Drugs Sales, Revenue and Gross Margin (2021-2026)
  59. 4.10.4 Bat Medical Peripheral Vasodilator Drugs Product Portfolio
  60. 4.10.5 Bat Medical Recent Developments
  61. 4.11 AstraZeneca
  62. 4.11.1 AstraZeneca Company Information
  63. 4.11.2 AstraZeneca Business Overview
  64. 4.11.3 AstraZeneca Peripheral Vasodilator Drugs Sales, Revenue and Gross Margin (2021-2026)
  65. 4.11.4 AstraZeneca Peripheral Vasodilator Drugs Product Portfolio
  66. 4.11.5 AstraZeneca Recent Developments
  67. 4.12 Viatris, Inc.
  68. 4.12.1 Viatris, Inc. Company Information
  69. 4.12.2 Viatris, Inc. Business Overview
  70. 4.12.3 Viatris, Inc. Peripheral Vasodilator Drugs Sales, Revenue and Gross Margin (2021-2026)
  71. 4.12.4 Viatris, Inc. Peripheral Vasodilator Drugs Product Portfolio
  72. 4.12.5 Viatris, Inc. Recent Developments
  73. 4.13 Sun Pharmaceutical Industries Ltd.
  74. 4.13.1 Sun Pharmaceutical Industries Ltd. Company Information
  75. 4.13.2 Sun Pharmaceutical Industries Ltd. Business Overview
  76. 4.13.3 Sun Pharmaceutical Industries Ltd. Peripheral Vasodilator Drugs Sales, Revenue and Gross Margin (2021-2026)
  77. 4.13.4 Sun Pharmaceutical Industries Ltd. Peripheral Vasodilator Drugs Product Portfolio
  78. 4.13.5 Sun Pharmaceutical Industries Ltd. Recent Developments
  79. 4.14 Merck & Co., Inc.
  80. 4.14.1 Merck & Co., Inc. Company Information
  81. 4.14.2 Merck & Co., Inc. Business Overview
  82. 4.14.3 Merck & Co., Inc. Peripheral Vasodilator Drugs Sales, Revenue and Gross Margin (2021-2026)
  83. 4.14.4 Merck & Co., Inc. Peripheral Vasodilator Drugs Product Portfolio
  84. 4.14.5 Merck & Co., Inc. Recent Developments
  85. 4.15 Lupin
  86. 4.15.1 Lupin Company Information
  87. 4.15.2 Lupin Business Overview
  88. 4.15.3 Lupin Peripheral Vasodilator Drugs Sales, Revenue and Gross Margin (2021-2026)
  89. 4.15.4 Lupin Peripheral Vasodilator Drugs Product Portfolio
  90. 4.15.5 Lupin Recent Developments
  91. 4.16 Bristol-Myers Squibb Company
  92. 4.16.1 Bristol-Myers Squibb Company Company Information
  93. 4.16.2 Bristol-Myers Squibb Company Business Overview
  94. 4.16.3 Bristol-Myers Squibb Company Peripheral Vasodilator Drugs Sales, Revenue and Gross Margin (2021-2026)
  95. 4.16.4 Bristol-Myers Squibb Company Peripheral Vasodilator Drugs Product Portfolio
  96. 4.16.5 Bristol-Myers Squibb Company Recent Developments
  97. 4.17 Boehringer Ingelheim International GmbH
  98. 4.17.1 Boehringer Ingelheim International GmbH Company Information
  99. 4.17.2 Boehringer Ingelheim International GmbH Business Overview
  100. 4.17.3 Boehringer Ingelheim International GmbH Peripheral Vasodilator Drugs Sales, Revenue and Gross Margin (2021-2026)
  101. 4.17.4 Boehringer Ingelheim International GmbH Peripheral Vasodilator Drugs Product Portfolio
  102. 4.17.5 Boehringer Ingelheim International GmbH Recent Developments
  103. 4.18 Abbott Laboratories
  104. 4.18.1 Abbott Laboratories Company Information
  105. 4.18.2 Abbott Laboratories Business Overview
  106. 4.18.3 Abbott Laboratories Peripheral Vasodilator Drugs Sales, Revenue and Gross Margin (2021-2026)
  107. 4.18.4 Abbott Laboratories Peripheral Vasodilator Drugs Product Portfolio
  108. 4.18.5 Abbott Laboratories Recent Developments
5 Global Peripheral Vasodilator Drugs Market Scenario by Region
  1. 5.1 Global Peripheral Vasodilator Drugs Market Size by Region: 2021 VS 2025 VS 2032
  2. 5.2 Global Peripheral Vasodilator Drugs Sales by Region: 2021-2032
  3. 5.2.1 Global Peripheral Vasodilator Drugs Sales by Region: 2021-2026
  4. 5.2.2 Global Peripheral Vasodilator Drugs Sales by Region: 2027-2032
  5. 5.3 Global Peripheral Vasodilator Drugs Revenue by Region: 2021-2032
  6. 5.3.1 Global Peripheral Vasodilator Drugs Revenue by Region: 2021-2026
  7. 5.3.2 Global Peripheral Vasodilator Drugs Revenue by Region: 2027-2032
  8. 5.4 North America Peripheral Vasodilator Drugs Market Facts & Figures by Country
  9. 5.4.1 North America Peripheral Vasodilator Drugs Market Size by Country: 2021 VS 2025 VS 2032
  10. 5.4.2 North America Peripheral Vasodilator Drugs Sales by Country (2021-2032)
  11. 5.4.3 North America Peripheral Vasodilator Drugs Revenue by Country (2021-2032)
  12. 5.4.4 United States
  13. 5.4.5 Canada
  14. 5.4.6 Mexico
  15. 5.5 Europe Peripheral Vasodilator Drugs Market Facts & Figures by Country
  16. 5.5.1 Europe Peripheral Vasodilator Drugs Market Size by Country: 2021 VS 2025 VS 2032
  17. 5.5.2 Europe Peripheral Vasodilator Drugs Sales by Country (2021-2032)
  18. 5.5.3 Europe Peripheral Vasodilator Drugs Revenue by Country (2021-2032)
  19. 5.5.4 Germany
  20. 5.5.5 France
  21. 5.5.6 U.K.
  22. 5.5.7 Italy
  23. 5.5.8 Russia
  24. 5.5.9 Spain
  25. 5.5.10 Netherlands
  26. 5.5.11 Switzerland
  27. 5.5.12 Sweden
  28. 5.5.13 Poland
  29. 5.6 Asia Pacific Peripheral Vasodilator Drugs Market Facts & Figures by Country
  30. 5.6.1 Asia Pacific Peripheral Vasodilator Drugs Market Size by Country: 2021 VS 2025 VS 2032
  31. 5.6.2 Asia Pacific Peripheral Vasodilator Drugs Sales by Country (2021-2032)
  32. 5.6.3 Asia Pacific Peripheral Vasodilator Drugs Revenue by Country (2021-2032)
  33. 5.6.4 China
  34. 5.6.5 Japan
  35. 5.6.6 South Korea
  36. 5.6.7 India
  37. 5.6.8 Australia
  38. 5.6.9 Taiwan
  39. 5.6.10 Southeast Asia
  40. 5.7 South America Peripheral Vasodilator Drugs Market Facts & Figures by Country
  41. 5.7.1 South America Peripheral Vasodilator Drugs Market Size by Country: 2021 VS 2025 VS 2032
  42. 5.7.2 South America Peripheral Vasodilator Drugs Sales by Country (2021-2032)
  43. 5.7.3 South America Peripheral Vasodilator Drugs Revenue by Country (2021-2032)
  44. 5.7.4 Brazil
  45. 5.7.5 Argentina
  46. 5.7.6 Chile
  47. 5.8 Middle East and Africa Peripheral Vasodilator Drugs Market Facts & Figures by Country
  48. 5.8.1 Middle East and Africa Peripheral Vasodilator Drugs Market Size by Country: 2021 VS 2025 VS 2032
  49. 5.8.2 Middle East and Africa Peripheral Vasodilator Drugs Sales by Country (2021-2032)
  50. 5.8.3 Middle East and Africa Peripheral Vasodilator Drugs Revenue by Country (2021-2032)
  51. 5.8.4 Egypt
  52. 5.8.5 South Africa
  53. 5.8.6 Israel
  54. 5.8.7 Türkiye
  55. 5.8.8 GCC Countries
6 Segment by Type
  1. 6.1 Global Peripheral Vasodilator Drugs Sales by Type (2021-2032)
  2. 6.1.1 Global Peripheral Vasodilator Drugs Sales by Type (2021-2032) & (k units)
  3. 6.1.2 Global Peripheral Vasodilator Drugs Sales Market Share by Type (2021-2032)
  4. 6.2 Global Peripheral Vasodilator Drugs Revenue by Type (2021-2032)
  5. 6.2.1 Global Peripheral Vasodilator Drugs Sales by Type (2021-2032) & (US$ Million)
  6. 6.2.2 Global Peripheral Vasodilator Drugs Revenue Market Share by Type (2021-2032)
  7. 6.3 Global Peripheral Vasodilator Drugs Price by Type (2021-2032)
7 Segment by Application
  1. 7.1 Global Peripheral Vasodilator Drugs Sales by Application (2021-2032)
  2. 7.1.1 Global Peripheral Vasodilator Drugs Sales by Application (2021-2032) & (k units)
  3. 7.1.2 Global Peripheral Vasodilator Drugs Sales Market Share by Application (2021-2032)
  4. 7.2 Global Peripheral Vasodilator Drugs Revenue by Application (2021-2032)
  5. 7.2.1 Global Peripheral Vasodilator Drugs Sales by Application (2021-2032) & (US$ Million)
  6. 7.2.2 Global Peripheral Vasodilator Drugs Revenue Market Share by Application (2021-2032)
  7. 7.3 Global Peripheral Vasodilator Drugs Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
  1. 8.1 Peripheral Vasodilator Drugs Value Chain Analysis
  2. 8.1.1 Peripheral Vasodilator Drugs Key Raw Materials
  3. 8.1.2 Raw Materials Key Suppliers
  4. 8.1.3 Peripheral Vasodilator Drugs Production Mode & Process
  5. 8.2 Peripheral Vasodilator Drugs Sales Channels Analysis
  6. 8.2.1 Direct Comparison with Distribution Share
  7. 8.2.2 Peripheral Vasodilator Drugs Distributors
  8. 8.2.3 Peripheral Vasodilator Drugs Customers
9 Global Peripheral Vasodilator Drugs Analyzing Market Dynamics
  1. 9.1 Peripheral Vasodilator Drugs Industry Trends
  2. 9.2 Peripheral Vasodilator Drugs Industry Drivers
  3. 9.3 Peripheral Vasodilator Drugs Industry Opportunities and Challenges
  4. 9.4 Peripheral Vasodilator Drugs Industry Restraints
10 Report Conclusion
    11 Disclaimer

      GET THE RESEARCH

      Choose your license.

      Choose who needs access.
      All options are for this report and research series.

      Compare access permissions.

      Single User License
      One named user. Individual access.
      Multi User License
      Up to 5 users in the same department.
      Enterprise License
      Organization-wide access within the agreed license.

      Access applies to the purchased edition. Later editions are separate purchases.

      License options
      $2,950USD
      Buy now

      PDF by email within 3–5 working days after payment confirmation.

      Talk to an analyst
      APO Research
      Talk to an analyst